Client News

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026

Together We Build: Rentschler Biopharma celebrates Milford site progress and growth since U.S. expansion

MIG Capital Continues Successful Course in 2025 Despite a Challenging Market Environment

Newron presents 2025 financial results and provides 2026 outlook

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Repronovo appoints Mark Altmeyer as chairman of the board

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026

Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard